There are 7 million Alzheimer's patients in the EU and 7 million in the U.S.. Assuming that Blarcamesine is sold at $10,000.00/patient/year, which is cheap compared to lecanemab ($26,500.00/patient/year), this would result in a revenue of $140bn. P/S ratio of 5 gives you $700bn market cap. Divided by 85mn shares outstanding is a share price of $8,200.00. Am I too naive/optimistic here?
Market Data 
Markets 
AI
